Source - SMW
Oxford BioMedica noted an announcement by Novartis that its Kymriah cancer treatment had received a priority review from US and European regulators. 

Oxford BioMedica is the sole manufacturer of the lentiviral vector that encodes part of the treatment.

At 9:37am: (LON:OXB) Oxford BioMedica PLC share price was +0.22p at 9.78p